All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View AML content recommended for you
Results from an open-label, single-arm, phase II pilot trial (NCT03672539) evaluating CPX-351 + gemtuzumab ozogamicin (GO) in adults with relapsed/refractory (R/R) CD33-positive (CD33+) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome with increased blasts (MDS-IB) after hypomethylating agent (HMA) failure were published in Blood Neoplasia by Alvarado et al. The primary efficacy endpoint was the overall response rate (ORR); safety was a coprimary endpoint.
Key data: In the overall cohort (AML, n = 48; MDS-IB, n = 2), the primary endpoint was met, with an ORR of 30%; the composite complete response (CRc) rate in the AML cohort was 19%. At a median estimated follow-up of 43.3 months, median event-free survival (EFS) and median overall survival (OS) were 1.7 and 5.7 months, respectively; among responders, the median duration of response (DoR) was 6.2 months. Overall, 4% of patients proceeded to hematopoietic stem cell transplantation (HSCT). Grade ≥3 nonhematological adverse events (AEs) occurred in 90% of patients, with infection-related AEs being the most common (74%) and no hepatic sinusoidal obstruction syndrome (SOS) events.
Key learning: In this trial, CPX-351 + GO demonstrated clinical activity in heavily pretreated patients with R/R CD33+ AML or high-risk MDS-IB after HMA failure, achieving a CRc rate of 19% in the AML subgroup, with AEs consistent with expectations for salvage treatment. However, responses were of limited duration, and few patients proceeded to HSCT. The combination may represent a salvage option for selected patients with R/R AML without adverse-risk genomics or targetable aberrations, or those with disease progression following targeted therapy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Where do you see the greatest future value for NGS-based MRD assessment in AML/MDS?